JNJ · News · 20260817N

Competition and Market Position

JOHNSON & JOHNSON · 2026-08-17 · Importance 51 · Surprise 74

Johnson & Johnson’s FDA-cleared Ottava surgical robot is described as a significant new rival to Intuitive Surgical’s da Vinci system in soft-tissue surgery. The competitive development contributed to a 30% decline in Intuitive Surgical’s stock during 2026, according to the cited report, despite Intuitive reporting 19% revenue growth. The article identifies future U.S. procedure growth and the speed at which Ottava gains market share as key competitive variables.

Key facts